Pfizer Gets Metsera: Why The $20.65 CVR Is Highly Likely To Pay Out (In Part)

Pfizer Inc. acquires Metsera, Inc., beating Novo Nordisk, for up to $86.25/share. Click for my analysis of the deal and what ...
JSTOR Daily

The Firm's Cost Function: A Successful Reconstruction?

This is a preview. Log in through your library . Journal Information The Journal of Business ceased publication with the November 2006 issue (Volume 79, Number 6). Founded in 1928, The Journal of ...
Semiconductor Engineering

AI In Test Analytics: Promise Vs. Reality

The hybrid model is emerging as the framework for trustworthy AI in test analytics. It retains traceability and supports ...

Decoding Tata Motors demerger: What investors need to know about cost of acquisition

Following Tata Motors’ demerger, shareholders now hold separate stakes in Tata Motors Limited (Commercial Vehicles) and Tata ...
BMJ Global Health

Cost-effectiveness of modified fully oral 9-month treatment regimens for rifampicin-resistant tuberculosis in Belarus, Georgia, Kazakhstan and the Republic of Moldova

Introduction Prior to 2020, treatment options for multidrug-resistant tuberculosis (MDR-TB) were limited and typically ...
Yahoo! Sports

Get to the Points!

We're here to help you win more at fantasy football — and have fun doing it. Award-winning analyst Scott Pianowski will deliver actionable advice to entertain, inform and assist in drafting, lineup ...